Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 809

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 809
---
 Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 11(a)of the Warrant to which this notice relates.

| Dated:          |
| Name of Holder: |
| By:             |
| Name:           |
| Title:          |

(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) F-13

Annex G

[CERTAIN INFORMATION IN THIS EXHIBIT IDENTIFIED BY [***] IS CONFIDENTIAL AND HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THAT INFORMATION AS PRIVATE OR CONFIDENTIAL.]

Execution

INTELLECTUAL PROPERTY LICENSE AGREEMENT

BETWEEN

WUXI BIOLOGICS (SHANGHAI FX) CO., LTD.

AND

AADI BIOSCIENCE, INC.

G-1

EXECUTION INTELLECTUAL PROPERTY LICENSE AGREEMENT THIS INTELLECTUAL PROPERTYLICENSEAGREEMENT (“ Agreement”) dated as of December 19, 2024 (“ Effective Date”), is entered into between WuXi Biologics (Shanghai FX) Co., Ltd., a corporation organized and existing under the laws of China, having offices at Room 2481, Building No.1,1150 Lan Feng Road, Fengxian District, Shanghai, 201403, China (“ WuXi Biologics”) and Aadi Bioscience, Inc., a Delaware corporation having offices at 2 Headquarters Plaza, East Building, 11 thFloor, Morristown, NJ 07960 (“ Aadi”). BACKGROUND

| A. | WuXi Biologics has pre-clinical stage development                                                                                                    
 programs relating to antibody drug conjugates targeting each of Mucin-16 (“MUC16”), Protein Tyrosine Kinase 7 (“PTK7”) and Seizure Related 6 Homolog 
 (“SEZ6”), and Controls certain patents, know-how and other intellectual property related to each of these programs.                                  |

| B. | Aadi desires to obtain an exclusive license to the patents, know-how                                                                                             
 and other intellectual property Controlled by WuXi Biologics relating to